Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.

ABSTRACT:

Background

Therapeutic options for inflammatory bowel disease (IBD) have increased since the introduction of tumour necrosis factor (TNF) inhibitors a few decades ago. However, direct comparisons of the effectiveness of second-line biological agents in patients with ulcerative colitis (UC) and Crohn's disease (CD) are lacking.

Methods

Patients with UC or CD who experienced anti-TNF treatment failure and subsequently used vedolizumab, ustekinumab, or tofacitinib as a second-line drug were retrospectively recruited. The primary outcomes were the clinical remission rate at week 16 and the cumulative relapse rate 48 weeks after receiving induction therapy.

Results

A total of 94 patients with UC or CD experienced anti-TNF treatment failure and received vedolizumab (UC: 37;

SUBMITTER: Hyun HK 

PROVIDER: S-EPMC8958783 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature